Idiopathic short stature (ISS) refers to children with shorten growth
of body where the reason behind the physical condition is unknown.
The children with height less than 2 standard deviations (SDs) are
categorized in this clinical condition. The group of idiopathic short
children includes children with delay of growth and puberty,
hereditary short stature, children with subtle cartilage and bone
dysplasias. There is no precise medical cause for ISS, whereas some
reasons include genetic structure and other orthopedic related
complications.
The disease often diagnosed by X-rays of the left wrist or hand along
with complete blood count, growth hormone stimulation test, insulin
growth factor-1 test and other blood related tests. Though there is
ongoing debate about treatment of ISS based on growth hormones but
based on the physical and blood test, generally hormonal therapy is
recommended by health care professionals In 2003, United States Food
and Drug Administration (FDA) approved human growth hormone treatment
for children with idiopathic short stature (height below 2.25 SD).
According to survey conducted by European Society of Endocrinologist,
94% physicians prefer growth hormone treatment for ISS.
Children with idiopathic short stature can be found in all parts of
the world. According to The Endocrine Society based in United States,
It is estimated that approximately 60 – 80% of all children across
the globe with short stature fit in the category of ISS and therefore
total number of people living with ISS will increase accordingly. The
above fact stands for demand of various treatment options for ISS
globally. The heavy investment in research and development, suitable
reimbursement conditions and growing number of patients living with
ISS may drive the growth of the market. On the other hand limited
awareness and lack of specific treatment may hinder the growth of the
overall market.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2641
Currently there are many clinical research projects under study that
are focused on developing specific treatment for idiopathic short
stature. Merck KGaA has “Saizen” in pipeline for treatment of
affected children, Pfizer in collaboration with prestigious Rabin
Medical Center exploring the use of biochemical markers of growth
with growth hormone treatment, Eli Lilly and Company trying to
develop monotherapy of somatropin in pubertal children with ISS,
Dong-A Pharmaceutical Co., Ltd. is studying the improvement of height
of children by growth hormone therapy.
Idiopathic short stature market can be segmented according to
different categories such as regional geography, classification of
ISS and categories of drugs available for the treatment.
Geographically, this market can be segmented in four regions namely
North American, Europe, Asia-Pacific and Rest of the World, out of
all these segments North America region have highest contribution in
terms of value because of high awareness, higher percentage of total
income spent on healthcare compared to other economies and
appropriate reimbursement circumstances. Followed by this, Europe,
Asia-Pacific and Rest of the World respectively could be major
segments of the market. The treatment market can also be segmented
according to categories such as familial ISS and non-familial ISS.
According to treatment options available, the market for ISS can be
segmented in Growth hormones, genetic therapy and others.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2641
Currently many established players in pharmaceuticals market which
are either catering or on the way to develop drugs for idiopathic
short stature. Out of these companies, JCR Pharmaceuticals Co.,
Braasch Biotech LLC, Bolder Biotechnology, Inc., Myungmoon
pharmaceutical Co. Ltd, Eli Lilly, Pfizer are leading contributors.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment